XPose Therapeutics

We are excited to feature in the latest August 2025 issue of Life Sciences Insights, published by California Life Sciences (CLS). Our article “AI Drug Discovery & Development for DNA Damage Response (DDR) Oncology Therapeutics” (https://lnkd.in/gsC3XGC4) on page 14, highlights our efforts to combine our multimodal experimental data for AIDD. This edition, AI in Action: Real-World Innovation in Life Sciences, explores how artificial intelligence is transforming discovery, operations, and patient outcomes across the sector. We are honored to contribute to this important conversation and share our perspective alongside other industry leaders (read the full issue here https://lnkd.in/gc65PVQV). #drugdiscovery #therapeutics Accelero Biostructures XPose Therapeutics

It has been studied and published for some time by different groups that inhibiting TLS DDR polymerase Pol eta (or Pol H, POLH, polymerase eta) can help reduce chemoresistance to chemotherapies like cisplatin, especially in ovarian cancer. This new research offers a related approach: instead of inhibiting Pol eta directly, inhibiting the PCNA-Pol eta PPI interface with a Pol eta-derived peptide. #oncology #therapeutics #drugdiscovery https://lnkd.in/g5DHFqXq

Interesting review on DDR proteins and their PPIs in the BER pathway, including clinically-validated targets PARP1 and APE1, with implications for novel oncology therapeutics. https://lnkd.in/g7uiTmT2 #oncology #therapeutics #drugdiscovery

Interesting new publication on “Predicting resistance to chemotherapy using chromosomal instability signatures” (https://lnkd.in/gfRf6T6y), pertaining to chemoresistance that arises from standard-of-care genotoxin/cytotoxin-based treatments involving cisplatin and other platinum-, taxane-, and anthracycline-based treatments. All the more reason to focus on the discovery and development of DDRi (DNA Damage Response inhibitors) as oncology therapeutics to get away from or alleviate the toxic effects of genotoxins. More details about this in our linked latest blog post “Chemoresistance in platinum-based cancer treatments and the role of discovery and development of novel DDRi (DNA Damage Response inhibitors)” #oncology #therapeutics #drugdiscovery

Work on discovery and development of new and specific PARP1 inhibitors to overcome hematological toxicity continues: “Discovery and Pharmacological Evaluation of Potent and Highly Selective PARP1 Inhibitors” https://lnkd.in/g-87d783 #oncology #therapeutics #drugdiscovery

Neat new results including APE1 and PARP1, which suggests how inhibition of APE1 and PARP1 together could be synergistic (already on our radar) due to abasic site cleavage by APE1 driving PARP1 hyperactivation. Additionally, results also demonstrate how there could be synergies in inhibition of ATR and APOBEC3B along with PARP1 and APE1. Plenty to explore in the discovery and development of novel therapeutics targeting DDR (DNA Damage Response). #oncology #therapeutics #drugdiscovery https://lnkd.in/gTM56F5n

“Why DNA Damage Response deserves renewed focus in cancer therapy” “DDR pathways are set to overcome resistance and alter treatment strategies…. now is the perfect moment to refocus on DDR, and how its potential to drive innovation in oncology could transform patient outcomes…. simultaneously targeting multiple DDR mechanisms or integrating DDR inhibitors into multimodal treatment strategies”: https://lnkd.in/gPkQrND4 #oncology #therapeutics #drugdiscovery